Filing Flows

Filing Flows › 8-K events › Eton Pharmaceuticals

Eton Pharmaceuticals: other events

Form 8-K filed Nov 2, 2026 · items 8.01

FDA decisionsEton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

What the filing says

Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Eton Pharmaceuticals at a glance

Latest quarterQ3 2026
Revenue$57.9M
Revenue Y/Y+158%
Operating margin39.7%
IndustryPharmaceutical Preparations

Eton Pharmaceuticals, Q3 2026: revenue $57.9M (+158% year over year), operating margin 39.7%. The chart follows the revenue to costs, profit and cash.

Eton Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.